Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.99 +1.53%

+$0.10 today

Market cap
$1.30B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 3.38M

Average 2.73M

TSHA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Taysha Gene Therapies, Inc.NASDAQ: TSHA

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$46.64M, compared with -$26.88M a year earlier. Trailing-twelve-month income before tax was -$149.63M.

Context

  • Income before tax amounted to 1115.3% of revenue in FY2025, up 43.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$46.64M or moves back toward the trailing-twelve-month quarterly average of -$37.41M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$46.64M-10.0% QoQ
Last fiscal yearDec 2025
-$109M-22.1% YoY
LTMJun 2026
-$149.63M-61.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-73.5%——
1 year-22.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(109M) USD
Year-over-year change
-22.1%

Income Before Tax vs competitors

How TSHA compares with its peers on the latest reported figures

  • TSHA's LTM Jun 2026 income before tax of -$149.63M is the 6th highest of the 9 companies compared; the peer median is -$107.58M.
  • Its year-over-year change of -61.4% is the 8th highest of 9, against a peer median of -6.6%.
  • Income before tax amounts to 2728.0% of revenue for TSHA, versus a peer median of 319.3%.
TSHA Competitors Peer median
Income Before Tax for TSHA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABEOAbeona Therapeutics Inc.LTM Mar 2026$66.24M +249.9%—455.6%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$24.47M +114.9%—1.1%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$48.88M -44.5%——
NGNENeurogene Inc.LTM Mar 2026-$98.64M -22.0%——
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-$116.52M -38.7%—319.3%
TSHATaysha Gene Therapies, Inc.LTM Jun 2026-$149.63M -61.4%—2728.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$160.9M +8.8%—182.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M +18.9%——
RGNXREGENXBIO Inc.LTM Mar 2026-$290.01M -83.9%—330.2%
Peer median (excluding TSHA) -$107.58M-6.6%—319.3%

Competitors are the stored peer set for TSHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue02.5M15.45M8.33M9.77M
Cost of Revenue02.49M000
Gross Profit015K15.45M8.33M9.77M
Gross Margin—0.6%100.0%100.0%100.0%
Research & Development131.94M91.17M56.78M66M86.4M
Selling, General & Admin41.32M34.87M30.05M28.95M33.87M
Operating Expenses173.27M126.04M87.89M99.79M120.27M
Depreciation & Amortization492K2.49M1.37M1.25M1.15M
EBITDA(172.6M)(159.73M)(105.2M)(87.95M)(107.79M)
EBITDA Margin—-6384.1%-680.8%-1055.5%-1102.9%
Operating Income(173.27M)(126.03M)(72.44M)(91.46M)(110.5M)
Operating Margin—-5037.1%-468.8%-1097.6%-1130.6%
Interest Income172K249K3.57M6.94M9.22M
Interest Expense1.43M3.8M5M102K63K
Other Income / Expenses(1.26M)(39.99M)(39.13M)2.16M1.5M
Income Before Tax(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Pre-Tax Margin—-6635.3%-722.1%-1071.6%-1115.3%
Income Tax Expense00000
Net Income(174.52M)(166.01M)(111.57M)(89.3M)(109M)
Net Margin—-6635.3%-722.1%-1071.6%-1115.3%
EPS (Basic)(4.64)(3.78)(0.96)(0.36)(0.34)
EPS (Diluted)(4.64)(3.78)(0.96)(0.36)(0.34)
Weighted Avg Shares37.65M43.95M116.12M250.13M319.71M
Weighted Avg Shares (Diluted)37.65M43.95M116.12M250.13M319.71M

Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Intrinsic Alpha fair value

Locked

Current Price

$3.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.